研究業績RESEARCH ACHIEVEMENT
柄山先生、矢澤先生、児嶌先生の論文がPublishされました。
呼吸器内科
2025.10.17
（柄山先生）
Karayama M, Miyashita K, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Suda T. Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study. Thorax. 2025 Oct 15:thorax-2025-223430. doi: 10.1136/thorax-2025-223430. Epub ahead of print. PMID: 41093568.
（矢澤先生）
Yazawa S, Enomoto N, Nakai S, Mochizuka Y, Fukada A, Tanaka Y, Naoi H, Inoue Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Furuhashi K, Toyoshima M, Kono M, Imokawa S, Fujii M, Akamatsu T, Koshimizu N, Yokomura K, Matsuda H, Kaida Y, Nakamura Y, Shirai M, Mori K, Masuda M, Fujisawa T, Inui N, Sugiura H, Sumikawa H, Kitani M, Tabata K, Ogawa N, Suda T. Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia. Sci Rep. 2025 Oct 13;15(1):35623. doi: 10.1038/s41598-025-19487-5. PMID: 41083568; PMCID: PMC12518612.
（児嶌先生：２編）
Kojima S, Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nishimoto K, Matsuura S, Hashimoto D, Matsui T, Asada K, Suda T. Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. BMC Cancer. 2025 Oct 1;25(1):1494. doi: 10.1186/s12885-025-14985-1. PMID: 41034823; PMCID: PMC12486796.
Kojima S, Inoue Y, Karayama M, Hashimoto D, Asada K, Matsuura S, Imokawa S, Matsui T, Matsuda H, Inami N, Kaida Y, Sato J, Ito Y, Fujii M, Toyoshima M, Yasui H, Suzuki Y, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Suda T. Biological aging and survival outcomes in patients with advanced non-small cell lung cancer receiving systemic therapy. Clinical Lung Cancer. Articles in Press, October 13, 2025.
Karayama M, Miyashita K, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Suda T. Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study. Thorax. 2025 Oct 15:thorax-2025-223430. doi: 10.1136/thorax-2025-223430. Epub ahead of print. PMID: 41093568.
（矢澤先生）
Yazawa S, Enomoto N, Nakai S, Mochizuka Y, Fukada A, Tanaka Y, Naoi H, Inoue Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Furuhashi K, Toyoshima M, Kono M, Imokawa S, Fujii M, Akamatsu T, Koshimizu N, Yokomura K, Matsuda H, Kaida Y, Nakamura Y, Shirai M, Mori K, Masuda M, Fujisawa T, Inui N, Sugiura H, Sumikawa H, Kitani M, Tabata K, Ogawa N, Suda T. Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia. Sci Rep. 2025 Oct 13;15(1):35623. doi: 10.1038/s41598-025-19487-5. PMID: 41083568; PMCID: PMC12518612.
（児嶌先生：２編）
Kojima S, Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nishimoto K, Matsuura S, Hashimoto D, Matsui T, Asada K, Suda T. Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. BMC Cancer. 2025 Oct 1;25(1):1494. doi: 10.1186/s12885-025-14985-1. PMID: 41034823; PMCID: PMC12486796.
Kojima S, Inoue Y, Karayama M, Hashimoto D, Asada K, Matsuura S, Imokawa S, Matsui T, Matsuda H, Inami N, Kaida Y, Sato J, Ito Y, Fujii M, Toyoshima M, Yasui H, Suzuki Y, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Suda T. Biological aging and survival outcomes in patients with advanced non-small cell lung cancer receiving systemic therapy. Clinical Lung Cancer. Articles in Press, October 13, 2025.